Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 847 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hyperlipidaemia Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Using a Telehealth and Shared Decision-Making Model to Address Preventative Medicine Strategies Among Communities in Louisiana

NCT05676970
View directory record Official record
Conditions
Preventative Medicine
Interventions
Telehealth: Personalized Preventative Medicine Strategies, TeleHealth: Preventative Medicine Education
Behavioral
Lead sponsor
Xavier University of Louisiana.
Other
Eligibility
18 Years to 55 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Nov 10, 2026, 1:38 PM EST
Completed Not applicable Interventional

Supermarket and Web-Based Intervention Targeting Nutrition (SuperWIN) for Cardiovascular Risk Reduction

NCT03895580
View directory record Official record
Conditions
Obesity, Hypertension, Hyperlipidemias, Diet Modification
Interventions
In-store POP education, Online POP education
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
21 Years to 75 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Nov 10, 2026, 1:38 PM EST
Completed Phase 3 Interventional Results available

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

NCT02392559
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
10 Years to 17 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
12
States / cities
Farmington, Connecticut • Wilmington, Delaware • Iowa City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Nov 10, 2026, 1:38 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Lipoprotein Interactions and Platelet Function in Healthy Individuals and Those With Lipid Disorders

NCT06747000
View directory record Official record
Conditions
Lipid Disorders
Interventions
Not listed
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 69 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
East Providence, Rhode Island • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Nov 10, 2026, 1:38 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol

NCT00006071
View directory record Official record
Conditions
Hypercholesterolemia, Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 10, 2026, 1:38 PM EST
Completed Phase 3 Interventional Results available

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

NCT02739984
View directory record Official record
Conditions
Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
Interventions
Evolocumab, Placebo to Evolocumab
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
46
States / cities
Tuscumbia, Alabama • Phoenix, Arizona • Lomita, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Nov 10, 2026, 1:38 PM EST
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Nov 10, 2026, 1:38 PM EST
Recruiting Phase 3 Interventional

Alirocumab in Patients on a Stable Dialysis Regimen

NCT03480568
View directory record Official record
Conditions
Hemodialysis, Peritoneal Dialysis, Hypercholesterolemia, Atherosclerotic Disease
Interventions
Alirocumab 150 MG/ML [Praluent]
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Nov 10, 2026, 1:38 PM EST
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)

NCT00819910
View directory record Official record
Conditions
Hypertriglyceridemia in Type 4 Hyperlipidemia, Non Diabetic Subjects With Normoglycemia
Interventions
Rosiglitazone, Placebo (Rosiglitazone), Placebo (Fenofibrate), Fenofibrate
Drug
Lead sponsor
Ahmad Slim
Federal
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Nov 10, 2026, 1:38 PM EST
Completed Phase 1 Interventional

Statin Therapy to Improve Medication Adherence

NCT01894217
View directory record Official record
Conditions
Hypercholesterolemia, HMG COA Reductase Inhibitor Adverse Reaction
Interventions
Genetic testing and reporting for SLCO1B1*5 allele
Genetic
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Nov 10, 2026, 1:38 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Validating the "Foods for Health" Portfolio of Functional Food Products

NCT02341924
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Portfolio of functional foods, Control foods
Other
Lead sponsor
University of Manitoba
Other
Eligibility
21 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Nov 10, 2026, 1:38 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Biological CVD Risk Factors in Older Depressed Patients

NCT00318864
View directory record Official record
Conditions
Depression, Hypertension, Hypercholesterolemia
Interventions
Cognitive behavioral therapy
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
55 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2006 · Synced Nov 10, 2026, 1:38 PM EST
Completed Phase 2 Interventional Results available

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

NCT01105975
View directory record Official record
Conditions
Dyslipidemia
Interventions
LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Nov 10, 2026, 1:38 PM EST
Completed Not applicable Interventional Results available

A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention

NCT03643705
View directory record Official record
Conditions
HIV/AIDS, Hypertension, Hyperlipidemias
Interventions
Multi-component intervention, General prevention education
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Nov 10, 2026, 1:38 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy

NCT02694094
View directory record Official record
Conditions
Hypercholesterolemia, Carotid Intimal Medial Thickness 1, Seizure, Epilepsy, Cardiovascular Disease, Cerebrovascular Disease, Heart Disease, Coronary Disease
Interventions
Modified Atkins or Ketogenic Diet
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 10, 2026, 1:38 PM EST
Completed Phase 3 Interventional Results available

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

NCT01763866
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
65
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Nov 10, 2026, 1:38 PM EST
Completed Phase 3 Interventional

A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

NCT03398005
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
CaPre, Placebo
Drug
Lead sponsor
Grace Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Nov 10, 2026, 1:38 PM EST
Completed No phase listed Observational

Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins

NCT00001154
View directory record Official record
Conditions
Hypolipoproteinemia, Hypercholesterolemia, Dyslipidemia, Hyperlipidemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1976
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 10, 2026, 1:38 PM EST
Completed Not applicable Interventional

Regeneron 1331 Kinetics Sub-Study HoFH

NCT04722068
View directory record Official record
Conditions
Hypercholesterolemia, Familial
Interventions
Kinetics test
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Nov 10, 2026, 1:38 PM EST
Completed Phase 2 Interventional Results available

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

NCT05694260
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Bempedoic acid
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Los Angeles, California • West Covina, California • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 10, 2026, 1:38 PM EST
Enrolling by invitation Not applicable Interventional

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

NCT06834204
View directory record Official record
Conditions
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
Interventions
PC2: Primary Care Connect
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 10, 2026, 1:38 PM EST
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

NCT03510884
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Nov 10, 2026, 1:38 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Phytosterol Supplementation and Cardiovascular Risk

NCT00153738
View directory record Official record
Conditions
Hypercholesteremia
Interventions
phytosterol
Drug
Lead sponsor
The Cooper Institute
Other
Eligibility
20 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Nov 10, 2026, 1:38 PM EST
Enrolling by invitation Not applicable Interventional

ECHO for Diabetes and Multiple Chronic Conditions Study

NCT06451458
View directory record Official record
Conditions
Diabetes Mellitus, Chronic Disease
Interventions
ECHO program for DMMC, Usual care
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 10, 2026, 1:38 PM EST